Elligo Health Research receives $16 million to expand its programs.

Austin, Texas-based Elligo Health Research is a company focused on expanded access to clinical trials. It has developed a platform that brings clinical research to the clinic by targeting the large percentage of physicians that are not involved in this research, with the goal of accelerating the development of new pharmaceutical, biotechnology and medical device products. The firm’s Elligo Goes Direct™ program uses electronic health records and other health data supported by personnel, procedures, technology and infrastructure to identify real-world patients and physicians for participation in clinical studies, so that these patients can participate in clinical trials while remaining under the care of their own physicians.

Elligo recently announced that it has raised $16 million in Series B funding led by Hatteras Venture Partners and Noro-Moseley Partners with participation from FS Healthcare LLC, Excelerate Health Ventures and all existing Series A investors. 

“Our programs speak specifically to the medical practices that are hesitant to perform research in their offices due to lack of resources and infrastructure,” said John Potthoff, Ph.D., CEO of Elligo. “The new funding will help us expand our services and not only make research studies more accessible to physician sites but also streamline data collection and submission processes.” 

Chad Moore, President of Elligo, added: “The investment will enable us to accelerate expansion of our network of physicians and refine our technology platform to improve study efficiency. And, every day we are one step — one study, one patient, one physician — closer to fulfilling our mission of improving clinical research and bringing new treatments to market faster by making it easier for physicians and patients to participate.”